{"title":"卡吡嗪在首发精神病中的作用","authors":"Rupali Rohatgi, Priyaranjan Avinash","doi":"10.4103/aip.aip_130_22","DOIUrl":null,"url":null,"abstract":"A newer atypical antipsychotic molecule, cariprazine has been approved by Food and Drug Administration for the treatment of schizophrenia and bipolar depression. The use of atypical antipsychotics has been the primary mode of intervention in the management of psychotic disorder in adolescents, adults, and geriatric population. For a better outcome in prognosis, this newer drug has now been playing an important role for the treatment of first episode psychosis.","PeriodicalId":52916,"journal":{"name":"Annals of Indian Psychiatry","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of cariprazine in first episode psychosis\",\"authors\":\"Rupali Rohatgi, Priyaranjan Avinash\",\"doi\":\"10.4103/aip.aip_130_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A newer atypical antipsychotic molecule, cariprazine has been approved by Food and Drug Administration for the treatment of schizophrenia and bipolar depression. The use of atypical antipsychotics has been the primary mode of intervention in the management of psychotic disorder in adolescents, adults, and geriatric population. For a better outcome in prognosis, this newer drug has now been playing an important role for the treatment of first episode psychosis.\",\"PeriodicalId\":52916,\"journal\":{\"name\":\"Annals of Indian Psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Indian Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/aip.aip_130_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Indian Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/aip.aip_130_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
A newer atypical antipsychotic molecule, cariprazine has been approved by Food and Drug Administration for the treatment of schizophrenia and bipolar depression. The use of atypical antipsychotics has been the primary mode of intervention in the management of psychotic disorder in adolescents, adults, and geriatric population. For a better outcome in prognosis, this newer drug has now been playing an important role for the treatment of first episode psychosis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
